2015 San Antonio Breast Cancer Symposium: Arimidex, Tamoxifen, and Recurrence Risk After DCIS

In this podcast, Marisa Weiss, M.D., Breastcancer.org’s chief medical officer, explains a study that looked at the effectiveness of Arimidex and tamoxifen for reducing risk after DCIS surgery and radiation, as well as the side effects of each medicine. The study was presented at the 2015 San Antonio Breast Cancer Symposium, December 8-12. Listen to the podcast to hear Dr. Weiss explain: what DCIS is why postmenopausal women should be reassured no matter which of these medicines they’re taking the side effects of each medicine